ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / IFRX / dividends
EVMN (31) IMRX (30) LFCR (59) CAMP (26) ⌘ Pro Terminal →

InflaRx N.V. (IFRX) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.77 +6.33% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.79

InflaRx N.V. (IFRX) carries a Roarable Rating of D+ (Sell) with 54/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $244.6M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IFRX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IFRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, InflaRx N.V. (NASDAQ: IFRX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $1.77 (+6.33% 1D, market cap $244.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IFRX ranks #219 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IFRX compare to EVMN and IMRX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IFRX carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EVMN (Evommune Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M) and IMRX (Immuneering Corporation (Class A)) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $242.5M). Among the 5-stock peer group, IFRX leads on earnings multiple (N/A) while EVMN leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IFRX?
▼

For InflaRx N.V. (IFRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #219 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.79 (+0.95%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 54/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.7% avg 90D alpha vs SPY • 51.0% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510054
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk C
Cash (12)Whales (7)SEC (13)Macro (13)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-1.7% Base Target
$3 Bull$2 Base$1 Bear
📬 FREE IFRX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IFRX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (54/100 Composite)
🔍 WHY IFRX SCORES 54/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (24% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (24% of score)

FRED Regime × Technicals: 45% of 52W Range • RSI-14 at 49.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Whale & Options Positioning7/20 pts (-13 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
46
Grade D$1.55-0.6% Next Q
Q2 (-2Q)
49
Grade D$1.54+7.8% Next Q
Q3 (-1Q)
51
Grade C-$1.66+6.6% Next Q
Current
54
Grade D+$1.77-0.7% Hist 90D α
Trajectory: D (46) → D+ (54)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IFRX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IFRX currently carries a cautious 54/100 (D+) rating due to Whale & Options Positioning (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.85) and Max Pain ($1.86) forces dealer call-delta covering toward $3.10.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IFRX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IFRX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 54%NO 46%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (6.8% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $19,307

Est. Year-10 Shareholder Yield: $348/yr
$10.7K
Yr 1
$11.4K
Yr 2
$12.2K
Yr 3
$13.0K
Yr 4
$13.9K
Yr 5
$14.8K
Yr 6
$15.8K
Yr 7
$16.9K
Yr 8
$18.1K
Yr 9
$19.3K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IFRX)

  • ✓Walkthrough of IFRX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IFRX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.90%▼ DESCENDING CHANNEL
2026-11-03O $1.71H $1.77L $1.66C $1.77VOL 691.5K
RES: $2.34SUP: $1.21SMA50: $1.85SMA200: $1.64
$3.08$2.55$2.03$1.50$0.98RES $2.34SUP $1.21$1.772026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IFRX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IFRX Butterfly Map → + Track IFRX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IFRX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IFRX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IFRX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IFRX)

Health Care Rank #219 of 1015 ⚔️ EVMN vs IFRX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IFRX vs. EVMN, IMRX, LFCR, CAMP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, InflaRx N.V. (IFRX) ranks #219 by composite RQD confidence (54/100, grade D+) and #545 by equity capitalization ($244.6M). Within this direct 5-issuer industry benchmark cohort, IFRX leads on earnings valuation at N/A trailing P/E, while EVMN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LFCR currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with IFRX at 54/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IFRX ACTIVE
InflaRx N.V.
D+ 54/100 — — — +6.33% $244.6M Benchmark Subject
EVMN
Evommune Inc.
E 31/100 — — -35.0% -10.70% $244.2M /evmn-vs-ifrx →
IMRX
Immuneering Corporation (Class A)
E 30/100 — — -35.0% -6.81% $242.5M /imrx-vs-ifrx →
LFCR
Lifecore Biomedical Inc.
C- 59/100 — — — -0.16% $242.3M /lfcr-vs-ifrx →
CAMP
CAMP4 Therapeutics Corporation
E 26/100 — — -35.0% -4.67% $248.5M /camp-vs-ifrx →

2. IFRX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

InflaRx N.V. (IFRX) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $244.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. IFRX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IFRX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, InflaRx N.V. (NASDAQ: IFRX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 54/100 at a spot price of $1.77 (+6.33% 1D, market cap $244.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 13/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, IFRX ranks #219 in composite RQD confidence.

How does IFRX compare to EVMN and IMRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IFRX carries a Roarable D+ (54/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, EVMN (Evommune Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $244.2M) and IMRX (Immuneering Corporation (Class A)) posts a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $242.5M). Among the 5-stock peer group, IFRX leads on earnings multiple (N/A) while EVMN leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IFRX?

For InflaRx N.V. (IFRX), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #219 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IFRX trading relative to its 50-day, 200-day, and 52-week technical levels?

IFRX last traded at $1.77 (+6.33% on volume of 799,798 shares), positioning the stock -4.32% below its 50-day simple moving average ($1.85) and +7.93% above its 200-day simple moving average ($1.64). Across its 52-week range of $0.80 to $2.95, IFRX sits at the 45.1% percentile with a 14-day RSI of 49.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.55 to $1.99).

Direct Sub-Reports: IFRX RQD Cockpit IFRX 12M Forecast IFRX Earnings & Move IFRX Dividends & DRIP IFRX Insiders & 13F IFRX Whale Options IFRX Profit Sankey IFRX News & Why
ROARABLE RATING BRIEF • RQD 54/100 (D+) ✓ SEC XBRL & RQD VERIFIED

IFRX — InflaRx N.V.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

InflaRx N.V. (IFRX) earns a live Roarable RQD composite score of 54/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $1.77 (+6.33% 1D, market capitalization $244.6M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (7/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sector: Health Care. Industry: Biotechnology: Pharmaceutical Preparations. Exchange: NASDAQ..V. Is a NASDAQ-listed issuer in this industry with a market capitalization of $0.3B.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 54/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 7/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 7/20, sustained execution supports upside toward the upper end of the $0.80 – $2.95 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care / Biotechnology classification and the beta of 1.0. — for any further ripple analysis.

  • Key Question #1: Can IFRX sustain or expand its — operating margin and — ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $2.95 52-week high?
  • Key Question #3: How sensitive is IFRX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IFRX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InflaRx N.V. (IFRX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IFRX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IFRX Bull vs. Bear Conversation Board — What's Your Call at $1.77?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IFRX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IFRX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $1.99 (+19.9%)
📌 Pinned Debate

The rating's forensic balance sheet pillar (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is its strongest reading, offering some def

Long IFRX at $1.66 targeting $1.99. The rating's forensic balance sheet pillar (Altman Z 2.5, Piotroski F 6/9, Debt/Equity 0.5) is its strongest reading, offering some defensive support despite zero ROIC and FCF yield.. Institutional whale score is 7/20 and the risk/reward vs. the $0.80 52-week low is skewed heavily in favor of bulls.

ArenaChamp_24 🐂 BULL

@ShortSeller_Dan Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (0.0%) holds, EPS grows into the multiple faster than bears think.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $1.41 (-15.1%)
Spot @ $1.66

With ROIC and FCF yield both at 0%, a 12/20 cash-engine score, and weak institutional and insider pillars, the RQD rating carries a "Tr

Here is the bear case nobody on the bull side wants to address on IFRX: With ROIC and FCF yield both at 0%, a 12/20 cash-engine score, and weak institutional and insider pillars, the RQD rating carries a "Trim" verdict.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%